Jack E. Geduldig
Impact in
- Genetics top 2%
- Glioma Diagnosis and Treatment
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Immune Cell Function and Interaction
Papers in
- Co-authors
- Peter N. Wiklund (6 shared papers)Kyrollis Attalla (6 shared papers)John P. Sfakianos (6 shared papers)Reza Mehrazin (6 shared papers)Annette S. Kim (1 shared paper)Mehdi Touat (1 shared paper)Kin-Hoe Chow (1 shared paper)Keith Lloyd Ligon (1 shared paper)
- Journals
- Urologic Oncology Seminars and Original Investigations (3 papers)British Journal of Urology (3 papers)Neuro-Oncology (2 papers)Nature (2 papers)Urology (1 paper)
- Partner nations
- United StatesSwedenFrance
In The Last Decade
Jack E. Geduldig
17 papers receiving 1.9k citations
Jack E. Geduldig's Hit Papers
Peers
Comparison fields: 5 of 81
- Genetics 624
- Immunology 864
- Oncology 817
- Cancer Research 249
- Molecular Biology 547
Countries citing papers authored by Jack E. Geduldig
This map shows the geographic impact of Jack E. Geduldig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack E. Geduldig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack E. Geduldig more than expected).
Fields of papers citing papers by Jack E. Geduldig
This network shows the impact of papers produced by Jack E. Geduldig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack E. Geduldig. The network helps show where Jack E. Geduldig may publish in the future.
Co-authors
The 25 scholars most cited alongside Jack E. Geduldig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial Hit paper breakdown → | 2018 | 1172 |
| 2 | Mechanisms and therapeutic implications of hypermutation in gliomas Hit paper breakdown → | 2020 | 494 |
| 3 | 2020 | 112 | |
| 4 | 2023 | 34 | |
| 5 | 2021 | 23 | |
| 6 | 2023 | 12 | |
| 7 | 2024 | 10 | |
| 8 | 2023 | 8 | |
| 9 | 2024 | 7 | |
| 10 | 2020 | 5 | |
| 11 | 2022 | 5 | |
| 12 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial | 2018 | 3 |
| 13 | 2024 | 2 | |
| 14 | 2025 | 2 | |
| 15 | 2025 | 2 | |
| 16 | 2023 | 1 | |
| 17 | 2024 | 1 |
About Jack E. Geduldig
Jack E. Geduldig is a scholar working on Genetics, Oncology, Cancer Research, Surgery and Behavioral Neuroscience, having authored 17 papers that have together received 1.9k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (6 papers), Bladder and Urothelial Cancer Treatments (4 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers), Extracellular vesicles in disease (1 paper) and PARP inhibition in cancer therapy (1 paper). The work is most often cited by research in Genetics (624 citations), Immunology (864 citations), Oncology (817 citations), Cancer Research (249 citations) and Molecular Biology (547 citations). Jack E. Geduldig has collaborated with scholars based in United States, Sweden and France. Frequent co-authors include Peter N. Wiklund, Kyrollis Attalla, John P. Sfakianos, Reza Mehrazin, Annette S. Kim, Mehdi Touat, Kin-Hoe Chow, Keith Lloyd Ligon, Seth W. Malinowski and Jordan Miller Rich. Their work appears in journals such as Urologic Oncology Seminars and Original Investigations, British Journal of Urology, Neuro-Oncology, Nature and Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.